Study Objective Studies on the use of direct oral anticoagulants (DOACs) in obese patients
are limited. Current guidelines advise against DOAC use in patients with a body weight …

Direct oral anticoagulant (DOAC) agents are becoming the anticoagulation strategy of
choice. However, their use in the treatment of acute venous thromboembolism (VTE) in …

Objective. To evaluate the effect of body weight (BW) on safety and efficacy of direct oral
anticoagulants (DOACs). Methods. We performed a meta-analysis of randomized controlled …

Purpose: There is limited clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy in …

There is limited data evaluating clinical outcomes of rivaroxaban versus warfarin in obese
patients with venous thromboembolism (VTE). Our objective was to evaluate the …

In clinical practice, direct oral anticoagulants (DOACs) are increasingly used for venous
thromboembolism treatment and prevention. A substantial proportion of patients with venous …

Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Purpose To review the literature on treatment of venous thromboembolism (VTE) and
prevention of cardioembolic stroke with direct-acting oral anticoagulants (DOACs) in low …

Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …

In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …